How Much Does Jatenzo Cost in Nevada in 2026?

Nevada Retail Pricing for Jatenzo

The average cash-pay price for Jatenzo across Nevada retail pharmacies sits at $900 per month in 2026, matching Tolmar's manufacturer list price. This figure applies to a 30-day supply of oral testosterone undecanoate capsules at standard dosing (158 mg or 237 mg twice daily with food).

Pricing varies minimally between major Nevada pharmacy chains. CVS, Walgreens, and independent pharmacies in Las Vegas, Reno, and Henderson all cluster within $870 to $930 for cash-pay customers without discount cards or insurance. The drug remains a Schedule III controlled substance under federal law, which adds dispensing requirements that prevent some mail-order discount strategies available for non-controlled medications. Nevada's Board of Pharmacy requires a valid prescription from a provider licensed in the state or holding appropriate telehealth credentials, though this does not appreciably affect final retail price 1.

Patients filling at specialty pharmacies may encounter slightly different pricing structures, particularly if the pharmacy participates in Tolmar's distribution network. The absence of an FDA-approved generic oral testosterone undecanoate means there is no lower-cost bioequivalent option at retail pharmacies. Testosterone undecanoate in injectable form (Aveed) exists but is a different product with a different route, dosing schedule, and price profile.

Nevada Medicaid and Jatenzo

Nevada Medicaid does not cover Jatenzo. The drug is absent from the Nevada Medicaid Preferred Drug List for 2026, and prior authorization requests for Jatenzo have historically been denied in favor of lower-cost testosterone formulations such as injectable testosterone cypionate or topical gels.

Nevada's Medicaid program, administered through the Division of Health Care Financing and Policy (DHCFP), covers injectable testosterone cypionate (approximately $30 to $75 per month) and select topical formulations as first-line therapy for male hypogonadism. The program's formulary logic follows a step-therapy requirement: patients must typically demonstrate failure of, intolerance to, or contraindication for at least one injectable or topical testosterone before the state will consider coverage of branded oral alternatives. Even with step-therapy documentation, Jatenzo approvals through Nevada Medicaid remain exceedingly rare based on available formulary data.

For Nevada Medicaid enrollees who specifically require oral testosterone (for example, patients with injection phobia, severe skin reactions to topical formulations, or conditions preventing intramuscular injection), the most viable path involves a provider-initiated appeal with documented clinical rationale. Success rates for these appeals are not publicly reported by the state, but anecdotal provider experience suggests they remain low. A 2020 pharmacokinetic study confirmed that oral testosterone undecanoate achieved physiologic testosterone levels in 87% of hypogonadal men at the 237 mg twice-daily dose, providing the clinical foundation for medical necessity arguments 1.

Commercial Insurance Coverage in Nevada

Coverage for Jatenzo through commercial insurance plans in Nevada varies by carrier and plan tier. UnitedHealthcare, Aetna, Cigna, and the major plans available through Nevada Health Link (the state's ACA marketplace) each maintain their own formulary placement for Jatenzo.

Most commercial plans that cover Jatenzo place it on Tier 3 (non-preferred brand) or Tier 4 (specialty), resulting in copays ranging from $75 to $250 per month after meeting the deductible. Prior authorization is nearly universal. The typical PA criteria include: confirmed diagnosis of hypogonadism with two morning serum testosterone levels below 300 ng/dL, documented trial of at least one first-line testosterone formulation, and prescriber attestation that oral administration is medically necessary 1.

Patients with high-deductible health plans (HDHPs) face the full $900 monthly cost until their deductible is met, at which point coinsurance (typically 20% to 40% for specialty-tier drugs) applies. For a patient on a $3,000 deductible HDHP, the effective annual out-of-pocket cost for Jatenzo can reach $3,000 to $5,000 depending on plan coinsurance rates and out-of-pocket maximums. Nevada's Silver-tier marketplace plans, the most commonly selected tier, generally carry $4,000 to $6,500 individual deductibles in 2026, meaning several months of full-price fills before insurance cost-sharing begins.

Employer-sponsored plans through large Nevada employers (MGM Resorts, Caesars Entertainment, Wynn Resorts, the State of Nevada itself) tend to offer better formulary access than individual marketplace plans, though specific coverage still requires verification through each plan's pharmacy benefit manager.

The Tolmar Savings Card Program

Tolmar Pharmaceuticals, Jatenzo's manufacturer, offers a savings card program that can reduce out-of-pocket costs for commercially insured patients. The card provides up to $500 off per prescription fill, potentially reducing copays to $0 for patients whose insurance copay falls at or below that threshold.

Eligibility requirements are straightforward but exclude certain populations. Patients must have commercial insurance (not government-funded coverage), be 18 years or older, and have a valid prescription for Jatenzo. The card cannot be used with Medicare Part D, Medicaid, TRICARE, or any other federal or state government-funded program. Nevada residents on employer-sponsored commercial plans or individual ACA marketplace plans (which are commercially administered despite receiving federal subsidies) typically qualify.

The card works at the point of sale. Patients present it alongside their insurance card at the pharmacy. The system adjudicates insurance first, then applies the savings card to the remaining patient responsibility. If insurance covers Jatenzo with a $150 copay, the savings card reduces the patient cost to $0. If the copay exceeds $500, the patient pays the difference. For cash-pay patients without insurance, Tolmar's published materials indicate the card may also provide a discount, though the specific cash-pay benefit amount varies and should be confirmed directly through the program at enrollment.

Enrollment is available online or by phone. The card must be renewed annually. Some patients report delays in activation at certain Nevada pharmacies, particularly smaller independents whose systems may not automatically recognize the card's BIN/PCN numbers. Calling the pharmacy in advance to confirm they can process the Tolmar card eliminates most point-of-sale friction.

Compounded Oral Testosterone Undecanoate in Nevada

Compounded oral testosterone undecanoate is available in Nevada through licensed 503A compounding pharmacies. This is legal under both federal and Nevada state pharmacy law, provided the pharmacy holds a valid Nevada Board of Pharmacy license and compounds pursuant to a valid patient-specific prescription.

503A pharmacies operate under section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding by licensed pharmacists when a prescriber determines that a commercially available product is not appropriate for a particular patient. Common clinical justifications include: need for a dose not commercially available (Jatenzo comes in 158 mg and 237 mg capsules only), allergy to an inactive ingredient in the branded product, or documented financial hardship 2.

Pricing for compounded oral testosterone undecanoate in Nevada varies by pharmacy but is substantially lower than brand Jatenzo. Some compounding pharmacies advertise costs between $50 and $200 per month depending on dose, capsule count, and whether the patient uses a membership or subscription model. The $0 figure sometimes cited reflects specific telehealth-plus-compounding bundles where the medication cost is rolled into a monthly membership fee.

Important clinical considerations apply. Compounded products do not undergo the same FDA review for bioequivalence, dissolution, or lymphatic absorption optimization that Jatenzo received during its NDA process. The Swerdloff et al. key trial that established Jatenzo's efficacy used the specific SEDDS (self-emulsifying drug delivery system) formulation, which enhances intestinal lymphatic uptake and avoids first-pass hepatic metabolism 1. Compounded versions may or may not replicate this delivery system. Patients switching from brand Jatenzo to a compounded version should have serum testosterone monitored 4 to 6 weeks after the switch to confirm therapeutic levels are maintained.

Nevada does not restrict compounding of testosterone undecanoate specifically, though all compounded testosterone preparations remain Schedule III controlled substances and require the same prescription, record-keeping, and reporting obligations as the branded product.

Telehealth Access to Jatenzo in Nevada

Nevada permits telehealth prescribing of Jatenzo. The state's telehealth laws, updated during and after the COVID-19 public health emergency, allow providers licensed in Nevada (or holding appropriate interstate licensure through the Interstate Medical Licensure Compact) to prescribe Schedule III controlled substances via audio-video telehealth encounters.

Several telehealth platforms operating in Nevada offer testosterone replacement therapy that includes Jatenzo as an option. These platforms typically conduct an initial video consultation, order confirmatory lab work (two morning total testosterone levels, plus LH, FSH, CBC, lipid panel, and PSA per Endocrine Society guidelines), and write prescriptions to either retail pharmacies or partner compounding pharmacies 3.

For Nevada patients in rural areas (Elko, Ely, Winnemucca, Pahrump), telehealth eliminates the geographic barrier to specialist endocrinology or urology care. The Nevada State Medical Board requires that the prescribing provider conduct an appropriate clinical evaluation before prescribing controlled substances via telehealth. An audio-only phone call does not satisfy this requirement for initial prescriptions of Schedule III drugs under current Nevada regulations.

The Ryan Haight Act's in-person examination requirement for controlled substances prescribed via telehealth was subject to a DEA proposed rule in 2023 that would create a permanent telemedicine exception. As of May 2026, practitioners prescribing Jatenzo via telehealth in Nevada should follow current DEA and state board guidance on examination requirements, which may differ from the temporary COVID-era flexibilities.

Cost-Reduction Strategies for Nevada Patients

Multiple approaches can lower the effective cost of testosterone replacement for Nevada residents who need oral formulation.

Strategy 1: Tolmar savings card plus commercial insurance. The combination of a Tier 3 formulary placement (copay $75 to $150) and the savings card ($500 maximum benefit) often results in $0 patient cost. This is the lowest-effort path for commercially insured patients.

Strategy 2: Compounded oral testosterone undecanoate. For patients without commercial insurance, or those whose plans do not cover Jatenzo at all, a compounded preparation from a Nevada-licensed 503A pharmacy at $50 to $200 per month represents significant savings over the $900 retail price. Requires monitoring to confirm therapeutic levels.

Strategy 3: Alternative testosterone formulations. If the oral route is not medically necessary, injectable testosterone cypionate ($30 to $75 per month, widely covered by Nevada Medicaid and all major commercial plans) or topical testosterone gel ($100 to $400 per month, frequently covered at Tier 2) offer lower-cost pathways. The Endocrine Society's 2018 clinical practice guidelines do not prefer one formulation over another for efficacy, noting that route selection should consider patient preference, cost, and adherence factors 3.

Strategy 4: Patient assistance programs. Tolmar offers a separate patient assistance program (PAP) for uninsured or underinsured patients with household income below 400% of the federal poverty level. Qualifying Nevada patients may receive Jatenzo at no cost through this program. Application requires income documentation and prescriber certification.

Strategy 5: Pharmacy benefit advocacy. Some Nevada-based patient advocacy services and pharmacy benefit consultants will file appeals on behalf of patients whose insurance denied Jatenzo coverage. Success rates improve when the appeal includes documentation of failed trials on two or more alternative formulations plus a letter of medical necessity from the prescribing provider.

Clinical Considerations for Nevada Prescribers

Jatenzo's FDA label carries specific monitoring requirements that affect ongoing cost. The label mandates blood pressure monitoring due to a dose-dependent increase in systolic BP observed in clinical trials. In the Swerdloff et al. registration trial, mean systolic BP increased by 3 to 5 mmHg in the treatment group versus placebo, with 7.6% of patients developing new-onset hypertension during the study period 1.

Nevada prescribers should factor monitoring costs into total treatment expense calculations when counseling patients. A basic metabolic panel, CBC, and lipid panel every 6 to 12 months (per Endocrine Society recommendations) adds approximately $150 to $300 annually in lab costs, depending on insurance coverage 3. The FDA label also requires periodic hematocrit monitoring given the known polycythemia risk with all exogenous testosterone formulations.

The oral route does offer one cost advantage over injectable testosterone undecanoate (Aveed): no in-office administration requirement. Aveed requires a 30-minute post-injection observation period due to pulmonary oil microembolism risk, adding office visit copays and time costs that Jatenzo eliminates. For Nevada patients weighing Jatenzo against Aveed specifically, the monthly cost comparison must include Aveed's administration fees ($200 to $500 per injection visit at Nevada urology and endocrinology practices, billed separately from the drug cost).

Dr. Ronald Swerdloff, who led the key pharmacokinetic and efficacy studies for oral testosterone undecanoate, noted in the 2020 publication: "Oral TU with a SEDDS formulation provides a convenient alternative to injectable and transdermal testosterone, achieving eugonadal levels in the majority of treated men without the hepatotoxicity concerns associated with older oral androgens" 1.

The Endocrine Society's 2018 guideline on testosterone therapy states: "We suggest offering testosterone therapy to men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" 3. This recommendation applies regardless of formulation choice and supports coverage arguments for Jatenzo when other routes have failed.